Bioapplications Inc.
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Sep 2033
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 9, 2027The maintenance fee for Vaccine composition for classical swine fever from plant and manufacturing method thereof (US 10,344,293) comes due Jan 9, 2027. Unpaid by Jul 9, 2027, it lapses early.
- 1 fee due Jun 19, 2027The maintenance fee for Recombinant Vector for Expressing Target Protein in Plant Cell (US 11,845,945) comes due Jun 19, 2027. Unpaid by Dec 20, 2027, it lapses early.
- 1 fee due Oct 16, 2027The maintenance fee for Recombinant canine parvovirus 2a VP2 and 2b VP2 antigen protein, and use thereof (US 11,958,883) comes due Oct 16, 2027. Unpaid by Apr 17, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,512,173 | Method for separating and purifying protein from plants using cellulose and cellulose binding domain In force · From the USPTO record | In force | From the USPTO record | |
| US 10,344,293 | Vaccine composition for classical swine fever from plant and manufacturing method thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 11,279,943 | Recombinant Vector for Expressing Target Protein in Plant Cell In force · High confidence | In force | High confidence | |
| US 11,845,945 | Recombinant Vector for Expressing Target Protein in Plant Cell In force · High confidence | In force | High confidence | |
| US 10,934,558 | Recombinant vector carrying cellulose binding domain and method for isolating and purifying protein, using same vector In force · From the USPTO record | In force | From the USPTO record | |
| US 10,857,217 | Antigen Fused with Porcine FC Fragment and Vaccine Composition Comprising the Same In force · Medium confidence | In force | Medium confidence | |
| US 10,947,278 | Recombinant vector comprising porcine FC fragment and preparation method of recombinant protein using thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 11,434,496 | Recombinant vector comprising BiP fragment and preparation method of recombinant proteins using thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 11,958,883 | Recombinant canine parvovirus 2a VP2 and 2b VP2 antigen protein, and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 12,385,056 | Method for Mass Production of Target Protein in Plant In force · High confidence | In force | High confidence |
Also on record, not counted in the 15: 1 patent in force now held by others · 5 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 4 abandoned · 4 no status recorded